



Global Health L i m i t e d

10th August, 2023

Ref:- GH/2023-24/EXCH/37

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Press Release

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release, for the Quarter ended June 30, 2023 Results of the Company.

Kindly take the above on record.





Thanking you,

Yours faithfully

For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a



Medanta delivers robust revenue growth and profitability in Q1FY24**Highest ever quarterly Total Income of Rs. 7,945 million in Q1 FY24; growth of 26.8% y-o-y and 8.6% sequentially****EBITDA of Rs. 1,993 million, up by 40.7% y-o-y; EBITDA margins expanded 250 bps y-o-y to 25.1%****Medanta and DLF to develop a 400 bed multi-specialty hospital in Delhi**

Gurugram, August 10th, 2023: Global Health Limited (NSE: [Medanta](#), BSE: [543654](#)), one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, today announced its unaudited consolidated financial results for the quarter ending 30th June, 2023.

Highlights of the Quarter Ended 30th June, 2023 (Q1 FY2024)

- Total income of Rs. 7,945 million; growth of 26.8% y-o-y
- EBITDA of Rs. 1,993 million; growth of 40.7% y-o-y
- EBITDA margins improved from 22.6% in Q1 FY23 to 25.1% in Q1 FY24
- Profit after tax was at Rs. 1,020 million; up by 73.7% y-o-y
- Average Occupied bed days increased by 16.2% y-o-y, representing an occupancy of 58.1% in Q1 FY24 on increased bed capacity
- ARPOB grew by 7.1% y-o-y to Rs 63,148; In-patient volume increased by 19.4% and Out-patient volume increased by 17.5% y-o-y
- Developing hospitals (Medanta Lucknow and Medanta Patna) revenue share increased from 23.4% in Q1 FY23 to 28.9% in Q1 FY24 amounting to Rs. 2,297 million. EBITDA share increased from 22.6% in Q1 FY23 to 31.4% in Q1 FY24 amounting to Rs. 720 million
- Revenue from international patients increased by 45% y-o-y to Rs. 477 million driven by increased volume and realization
- In-house out-patient pharmacy business continues to register strong growth. Revenue increased by 43% y-o-y from Rs. 186 million in Q1 FY23 to Rs. 266 million in Q1 FY24

Commenting on Q1 FY2024 results, Mr. Pankaj Sahni, Group CEO and Director said: “We are excited to partner with DLF to build a new 400 bed multi-super specialty hospital in South Delhi. This hospital will allow us to serve patients across the entire NCR belt by seamlessly linking our facilities in Gurgaon, Delhi and Noida. We are also pleased to report our Q1 FY24 financial performance. The Company continues to deliver strong year-on-year and sequential growth driven by higher patient volumes and improvement in realization.”

Key Developments – Q1 FY2024

- Medanta and DLF to develop ~400 beds super-specialty hospital in Delhi to further strengthen presence in NCR. GHIL and DLF will form a new company, both will contribute equity in equal proportion (50:50)
- This new facility will strengthen Medanta's presence in the National Capital Region of Delhi. Medanta will operate its Gurugram, Noida and Delhi facilities in a seamless manner linking its existing 1,391 bed flagship hospital in Gurugram and its upcoming Noida facility (550 beds) to the new hospital in South Delhi
- Medanta Lucknow launched Tele-ICU services with tie-ups across Jodhpur, Maharajganj and Prayagraj cities
- Comprehensive Oncology program launched at Medanta Lucknow with installation and operationalization of Siemens Varian EDGE Radiosurgery Machine for Radiation Oncology
- Launched first multi-service out-of-hospital retail pharmacy in DLF Cyber Park, Gurugram, which offers doctor consultation with Medanta experts, medicine delivery and lab services to corporate employees
- 28 new beds were added at Patna facility, with this total bed capacity at the group level increased to 2,725 from 2,697 in Q4 FY23
- Medanta Gurgaon received FICCI's Medical Value Travel Award for providing exceptional services to international patients

About Global Health Limited (Medanta)

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the "Company") is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled "An assessment of the healthcare delivery market in India, September 2022" by CRISIL Limited.

Under the "Medanta" brand, the Company has a network of five hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, and Patna). Spanning an area of 4.7 million sq. ft., its operational hospitals have 2,725 installed beds as on June 30, 2023. It also has one hospital under-construction in Noida. The Company provides healthcare services in over 30 medical specialties and engages over 1,600+ doctors led by highly experienced department heads.

For more information visit www.medanta.org or contact:

Adfactors

Sarbjeeet Sharma | Sarbjeeet.sharma@adfactors.pr.com | +91 22 6757 4444

Global Health Limited**Ravi Gothwal**ravi.gothwal@medanta.org

Tel: 0124 – 4141 414

Raunak Thakurraunak.thakur@medanta.org

Tel: 0124 – 4141 414

Safe Harbour Disclaimer

This press release, apart from historical information, contains some "forward-looking statements" including those describing the Company's strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.

These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.